$ACRX Up to date company activities and other impo
Post# of 94146
Posted On: 07/07/2014 10:48:42 AM
$ACRX Up to date company activities and other important information about $ACRX
$ACRX
DD Notes ~ http://www.ddnotesmaker.com/ACRX
##### recent news/filings ~ source: finance.yahoo.com
Mon, 07 Jul 2014 14:13:19 GMT ~ AcelRx's Upcoming PDUFA And Trade Recommendations
read full: http://seekingalpha.com/article/2301885-acelr...urce=yahoo
*********************************************************
Mon, 07 Jul 2014 07:00:00 GMT ~ AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for ZALVISO™
- REDWOOD CITY, Calif. and AACHEN, Germany, July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO™ for the management of moderate to severe acute pain in adult patients in a medically supervised environment. ZALVISOTM is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device. AcelRx and Grunenthal entered into license and supply agreements for ZALVISOTM in the EU, Australia and certain other countries in December 2013. After approval by EMA, AcelRx is eligible to receive approximately $200 million in additional milestone payments, based upon successful regulatory and product development efforts and net sales target achievements. Grunenthal will also make tiered royalty, supply and trademark fee payments in the mid-teens up to the twenty percent range, on net sales of ZALVISOTM in the Grunenthal territory.
read full: http://finance.yahoo.com/news/acelrx-grunenth...00533.html
*********************************************************
Mon, 07 Jul 2014 06:29:00 GMT ~ 2:29 am AcelRx and Grunenthal announce submission of European Marketing Authorization Application for ZALVISO
read full: http://finance.yahoo.com/news/inplay-briefing....html#acrx
*********************************************************
Wed, 02 Jul 2014 12:30:11 GMT ~ AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month
read full: http://seekingalpha.com/article/2296285-acelr...urce=yahoo
*********************************************************
Thu, 19 Jun 2014 11:00:00 GMT ~ AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference
- REDWOOD CITY, Calif., June 19, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will present a corporate overview on June 25th. Presentation details are as follows: AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso™, is designed to improve the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, during the second half of 2014. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs, please visit www.acelrx.com.
read full: http://finance.yahoo.com/news/acelrx-pharmace...00958.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=ACRX&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=ACRX&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ACRX/company-info
Ticker: $ACRX
OTC Market Place: Not Available
CIK code: not found
Company name: AcelRx Pharmaceuticals, Inc.
Incorporated In:
##### extra dd links
Latest filings: http://www.otcmarkets.com/stock/ACRX/filings
Latest financials: http://www.otcmarkets.com/stock/ACRX/financials
Latest news: http://www.otcmarkets.com/stock/ACRX/news - http://finance.yahoo.com/q/h?s=ACRX+Headlines
Major holdings: http://data.cnbc.com/quotes/ACRX/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ACRX+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ACRX.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ACRX
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=AcelRx+Pharmaceuti...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
Short Sales: http://www.otcmarkets.com/stock/ACRX/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ACRX/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ACRX/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ACRX+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ACRX+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ACRX+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ACRX+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ACRX+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ACRX+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ACRX
Balance Sheet: http://finance.yahoo.com/q/bs?s=ACRX
Cash Flow: http://finance.yahoo.com/q/cf?s=ACRX+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ACRX
Bloomberg: http://www.bloomberg.com/quote/ACRX:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ACRX
Bussinessweek: http://investing.businessweek.com/research/st...icker=ACRX
Barchart: http://www.barchart.com/quotes/stocks/ACRX
OTC Short Report: http://otcshortreport.com/index.php?index=ACRX
Investopedia: http://www.investopedia.com/markets/stocks/ACRX/?wa=0
http://www.pennystocktweets.com/stocks/profile/ACRX
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/ACRX
$ACRX
DD Notes ~ http://www.ddnotesmaker.com/ACRX
##### recent news/filings ~ source: finance.yahoo.com
Mon, 07 Jul 2014 14:13:19 GMT ~ AcelRx's Upcoming PDUFA And Trade Recommendations
read full: http://seekingalpha.com/article/2301885-acelr...urce=yahoo
*********************************************************
Mon, 07 Jul 2014 07:00:00 GMT ~ AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for ZALVISO™
- REDWOOD CITY, Calif. and AACHEN, Germany, July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO™ for the management of moderate to severe acute pain in adult patients in a medically supervised environment. ZALVISOTM is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device. AcelRx and Grunenthal entered into license and supply agreements for ZALVISOTM in the EU, Australia and certain other countries in December 2013. After approval by EMA, AcelRx is eligible to receive approximately $200 million in additional milestone payments, based upon successful regulatory and product development efforts and net sales target achievements. Grunenthal will also make tiered royalty, supply and trademark fee payments in the mid-teens up to the twenty percent range, on net sales of ZALVISOTM in the Grunenthal territory.
read full: http://finance.yahoo.com/news/acelrx-grunenth...00533.html
*********************************************************
Mon, 07 Jul 2014 06:29:00 GMT ~ 2:29 am AcelRx and Grunenthal announce submission of European Marketing Authorization Application for ZALVISO
read full: http://finance.yahoo.com/news/inplay-briefing....html#acrx
*********************************************************
Wed, 02 Jul 2014 12:30:11 GMT ~ AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month
read full: http://seekingalpha.com/article/2296285-acelr...urce=yahoo
*********************************************************
Thu, 19 Jun 2014 11:00:00 GMT ~ AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference
- REDWOOD CITY, Calif., June 19, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will present a corporate overview on June 25th. Presentation details are as follows: AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso™, is designed to improve the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, during the second half of 2014. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs, please visit www.acelrx.com.
read full: http://finance.yahoo.com/news/acelrx-pharmace...00958.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=ACRX&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=ACRX&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ACRX/company-info
Ticker: $ACRX
OTC Market Place: Not Available
CIK code: not found
Company name: AcelRx Pharmaceuticals, Inc.
Incorporated In:
##### extra dd links
Latest filings: http://www.otcmarkets.com/stock/ACRX/filings
Latest financials: http://www.otcmarkets.com/stock/ACRX/financials
Latest news: http://www.otcmarkets.com/stock/ACRX/news - http://finance.yahoo.com/q/h?s=ACRX+Headlines
Major holdings: http://data.cnbc.com/quotes/ACRX/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=ACRX+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/ACRX.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=ACRX
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=AcelRx+Pharmaceuti...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...als%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
Short Sales: http://www.otcmarkets.com/stock/ACRX/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/ACRX/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/ACRX/research
Historical Prices: http://finance.yahoo.com/q/hp?s=ACRX+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=ACRX+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=ACRX+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=ACRX+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=ACRX+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=ACRX+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=ACRX
Balance Sheet: http://finance.yahoo.com/q/bs?s=ACRX
Cash Flow: http://finance.yahoo.com/q/cf?s=ACRX+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/ACRX
Bloomberg: http://www.bloomberg.com/quote/ACRX:US
Morningstar: http://quotes.morningstar.com/stock/s?t=ACRX
Bussinessweek: http://investing.businessweek.com/research/st...icker=ACRX
Barchart: http://www.barchart.com/quotes/stocks/ACRX
OTC Short Report: http://otcshortreport.com/index.php?index=ACRX
Investopedia: http://www.investopedia.com/markets/stocks/ACRX/?wa=0
http://www.pennystocktweets.com/stocks/profile/ACRX
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/ACRX
(0)
(0)Scroll down for more posts ▼